Skip to main content
SpringerLink
Log in

Atypical Antipsychotics for Neuropsychiatric Symptoms of Dementia

Malignant or Maligned?

  • Leading Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Recent concerns regarding the use of atypical antipsychotics when used for the treatment of neuropsychiatric symptoms in dementia have led to a flurry of studies attempting to re-evaluate their place in therapy. We critically review current evidence on the safety profiles of these agents in patients with behavioural and psychological symptoms of dementia (BPSD) and provide recommendations to guide the clinician. Potential risks with this class of medications include extrapyramidal symptoms (EPS), weight gain, diabetes mellitus, cardiac conduction abnormalities (e.g. corrected QT [QTc] interval prolongation), cerebrovascular adverse events and mortality. Compared with placebo, treatment of BPSD with atypical antipsychotics leads to little or no increase in EPS and no significant weight change. Compared with typical antipsychotics, treatment of BPSD with atypical antipsychotics leads to a reduced risk of EPS, lower incidences of tardive dyskinesias and no significant weight gain. Atypical antipsychotics have not been associated with glucose intolerance, diabetes or hyperlipidaemia in elderly dementia patients. Both typical and atypical antipsychotics have been associated with cardiac conduction abnormalities, with the magnitude of QTc prolongation being slightly smaller with atypical antipsychotics. Randomised controlled trials suggest that atypical antipsychotics are associated with an increased risk of cerebrovascular adverse events, such as stroke, and an increased mortality compared with placebo. However, it appears that typical antipsychotics have similar risks of cerebrovascular adverse events and death. An increased risk of anticholinergic adverse effects and falls must also be considered with both typical and atypical antipsychotics. In summary, atypical antipsychotics are associated with potentially serious adverse events. Before prescribing these medications in elderly dementia patients, baseline EPS, ECG abnormalities and concomitant medications should be assessed, and the presence of cardiovascular, cerebrovascular and metabolic risk factors should be taken into consideration when benefits and risks are being weighed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Finkel SI, Costa e Silva J, Cohen G, et al. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 1996; 8Suppl. 3: 497–500

    PubMed  Google Scholar 

  2. Alexopoulos GS, Silver JM, Kahn DA, et al. The expert consensus guideline series: treatment of agitation in older persons with dementia. Postgrad Med 1998; 26: 1–88

    Google Scholar 

  3. Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias of late life: American Psychiatric Association. Am J Psychiatry 1997; 154: 1–39

  4. Herrmann N. Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci 2001; 28Suppl. 1: S96–107

    PubMed  Google Scholar 

  5. Consensus statement on improving the quality of mental health care in US nursing homes: management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc 2003; 51: 1287–98

  6. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293: 596–608

    Article  PubMed  CAS  Google Scholar 

  7. Lanctot KL, Best TS, Mittmann N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998; 59: 550–61

    Article  PubMed  CAS  Google Scholar 

  8. Alexopoulos GS, Streim J, Carpenter D, et al. Using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65Suppl. 2: 5–99

    PubMed  Google Scholar 

  9. Rapoport M, Mamdani M, Shulman KI, et al. Antipsychotic use in the elderly: shifting trends and increasing costs. Int J Geriatr Psychiatry 2005; 20: 749–53

    Article  PubMed  Google Scholar 

  10. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002; 167: 1269–70

    PubMed  Google Scholar 

  11. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004; 170: 1395

    PubMed  Google Scholar 

  12. Kuehn BM. FDA warns antipsychotic drugs may be risky for elderly. JAMA 2005; 293: 2462

    Article  PubMed  CAS  Google Scholar 

  13. Health Canada. Health Canada endorsed important safety information on atypical antipsychotic drugs and dementia [online]. Available from URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2005/atyp-antipsycho_hpc_e.html [Accessed 2005 Dec 5]

  14. Committee on Safety of Medicines. Summary of clinical trial data on cerebrovascular adverse events (CVAEs) in randomized clinical trials of risperidone conducted in patients with dementia [online]. Available from URL: http://www.mca.gov.uk/aboutagency/regframework/csm/csmhome.htm [Accessed 2004 Jun 28]

  15. Ames D, Ballard C, Cream J, et al. For debate: should novel antipsychotics ever be used to treat the behavioural and psychological symptoms of dementia? Int Psychogeriatr 2005; 17: 1, 3-29

    Article  Google Scholar 

  16. Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs 2005; 19: 91–103

    Article  PubMed  Google Scholar 

  17. Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000; 17: 363–84

    Article  PubMed  CAS  Google Scholar 

  18. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60: 107–15

    Article  PubMed  CAS  Google Scholar 

  19. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946–55

    Article  PubMed  Google Scholar 

  20. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64: 134–43

    Article  PubMed  CAS  Google Scholar 

  21. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000; 57: 968–76

    Article  PubMed  CAS  Google Scholar 

  22. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2004; 19: 115–26

    Article  PubMed  Google Scholar 

  23. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26: 494–504

    Article  PubMed  CAS  Google Scholar 

  24. Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med 2005; 165: 1882–8

    Article  PubMed  CAS  Google Scholar 

  25. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 52: 756–65

    Article  PubMed  CAS  Google Scholar 

  26. Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47: 716–9

    PubMed  CAS  Google Scholar 

  27. Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157: 1150–5

    Article  PubMed  CAS  Google Scholar 

  28. Street JS, Clark WS, Kadam DL, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer’s dementia. Int J Geriatr Psychiatry 2001; 16Suppl. 1: S62–70

    Article  PubMed  Google Scholar 

  29. Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias. J Clin Psychiatry 2005; 66: 633–7

    Article  PubMed  Google Scholar 

  30. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96

    PubMed  CAS  Google Scholar 

  31. Jeste DV, Barak Y, Madhusoodanan S, et al. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 2003; 11: 638–47

    PubMed  Google Scholar 

  32. Barak Y. No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. J Clin Psychiatry 2002; 63: 117–9

    Article  PubMed  Google Scholar 

  33. Deberdt WG, Dysken MW, Rappaport SA, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry 2005; 13: 722–30

    PubMed  Google Scholar 

  34. Goldberg RJ. Weight variance associated with atypical neuroleptics in nursing home dementia patients. J Am Med Dir Assoc 2001; 2: 26–8

    Article  PubMed  CAS  Google Scholar 

  35. Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol 2004; 14: 115–9

    Article  PubMed  CAS  Google Scholar 

  36. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002; 63: 920–30

    Article  PubMed  CAS  Google Scholar 

  37. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561–6

    Article  PubMed  Google Scholar 

  38. Etminan M, Streiner DL, Rochon PA. Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy 2003; 23: 1411–5

    Article  PubMed  CAS  Google Scholar 

  39. Barak Y, Aizenberg D. Effects of olanzapine on lipid abnormalities in elderly psychotic patients. Drugs Aging 2003; 20: 893–6

    Article  PubMed  CAS  Google Scholar 

  40. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013–22

    Article  PubMed  CAS  Google Scholar 

  41. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774–82

    Article  PubMed  CAS  Google Scholar 

  42. Yerrabolu M, Prabhudesai S, Tawam M, et al. Effect of risperidone on QT interval and QT dispersion in the elderly. Heart Dis 2000; 2: 10–2

    PubMed  CAS  Google Scholar 

  43. Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58: 1161–7

    Article  PubMed  CAS  Google Scholar 

  44. Liperoti R, Gambassi G, Lapane KL, et al. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Arch Intern Med 2005; 165: 696–701

    Article  PubMed  Google Scholar 

  45. Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005; 66: 1090–6

    Article  PubMed  Google Scholar 

  46. Layton D, Harris S, Wilton LV, et al. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharmacol 2005; 19: 473–82

    Article  PubMed  CAS  Google Scholar 

  47. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113–5

    Article  PubMed  Google Scholar 

  48. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330: 445

    Article  PubMed  Google Scholar 

  49. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934–43

    Article  PubMed  CAS  Google Scholar 

  50. Raivio MM, Laurila JV, Strandberg TE, et al. Psychotropic medication and stroke outcome. Am J Psychiatry 2005; 162: 1027

    Article  PubMed  Google Scholar 

  51. Nasrallah HA, White T, Nasrallah AT. Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data. Am J Geriatr Psychiatry 2004; 12: 437–9

    PubMed  Google Scholar 

  52. Suh GH, Shah A. Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home. Int Psychogeriatr 2005; 17: 429–41

    Article  PubMed  Google Scholar 

  53. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353: 2335–41

    Article  PubMed  CAS  Google Scholar 

  54. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18(2): 63–101

    Article  PubMed  CAS  Google Scholar 

  55. Mulsant BH, Gharabawi GM, Bossie CA, et al. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J Clin Psychiatry 2004; 65: 1708–14

    Article  PubMed  CAS  Google Scholar 

  56. Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer’s disease: randomised double blind placebo controlled trial. BMJ 2005; 330: 874

    Article  PubMed  CAS  Google Scholar 

  57. McShane R, Keene J, Gedling K, et al. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ 1997; 314: 266–70

    Article  PubMed  CAS  Google Scholar 

  58. Liu B, Anderson G, Mittmann N, et al. Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998; 351: 1303–7

    Article  PubMed  CAS  Google Scholar 

  59. Ray WA, Thapa PB, Gideon P. Benzodiazepines and the risk of falls in nursing home residents. J Am Geriatr Soc 2000; 48: 682–5

    PubMed  CAS  Google Scholar 

  60. Thapa PB, Gideon P, Fought RL, et al. Psychotropic drugs and risk of recurrent falls in ambulatory nursing home residents. Am J Epidemiol 1995; 142: 202–11

    PubMed  CAS  Google Scholar 

  61. Katz IR, Rupnow M, Kozma C, et al. Risperidone and falls in ambulatory nursing home residents with dementia and psychosis or agitation: secondary analysis of a double-blind, placebo-controlled trial. Am J Geriatr Psychiatry 2004; 12: 499–508

    PubMed  Google Scholar 

  62. Hien le TT, Cumming RG, Cameron ID, et al. Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc 2005; 53: 1290–5

    Article  PubMed  CAS  Google Scholar 

  63. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000; 356: 1219–23

    Article  PubMed  CAS  Google Scholar 

  64. Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Thromb Haemost 2002; 88: 205–9

    PubMed  CAS  Google Scholar 

  65. van Reekum R, Clarke D, Conn D, et al. A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. Int Psychogeriatr 2002; 14: 197–210

    Article  PubMed  Google Scholar 

  66. Ruths S, Straand J, Nygaard HA, et al. Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study. The Bergen District Nursing Home Study. J Am Geriatr Soc 2004; 52: 1737–43

    Article  PubMed  Google Scholar 

  67. Ballard CG, Thomas A, Fossey J, et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry 2004; 65: 114–9

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Drs Herrmann and Lanctot have received research support and/or honoraria from Janssen-Ortho, Eli Lilly, AstraZeneca, Novartis, Bristol-Myers Squibb and Pfizer, all makers of atypical antipsychotics. The authors have received no funding for the preparation of this review.

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Toronto, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada

    Nathan Herrmann & Krista L. Lanctôt

Authors
  1. Nathan Herrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Krista L. Lanctôt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nathan Herrmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herrmann, N., Lanctôt, K.L. Atypical Antipsychotics for Neuropsychiatric Symptoms of Dementia. Drug-Safety 29, 833–843 (2006). https://doi.org/10.2165/00002018-200629100-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200629100-00002

Keywords

Search

Navigation